MedTrace Logo

Different Endoscopic Gastric Cancer Risk Assessments

NCT05458388 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3500

Last updated 2022-07-14

No results posted yet for this study

Summary

The Kimura-Takamoto classification established in Japan can observe the extent of gastric atrophy in real-time under endoscopy, and diffuse atrophy also indicates an increased risk of gastric cancer. Recent studies have found that the evaluation of intestinal metaplasia score (EGGIM score) of various stomach parts by electronic staining can well identify OLGIM III\\ IV patients. Although the Kimura-Takamoto classification and EGGIM score can evaluate the risk of gastric cancer in patients, only in cross-sectional studies, it is not clear the diagnostic value of risk assessment in population screening. Early gastric cancer has the characteristics of hidden lesions and a high rate of clinical missed diagnosis. Concentrating high-risk groups through risk scores is expected to guide endoscopic doctors to conduct a targeted careful examination. However, it is not clear whether Kimura-Takamoto classification and EGGIM score can improve the detection rate of early gastric cancer in clinical practice.

Conditions

  • Gastric Cancer Screening

Interventions

PROCEDURE

Kimura-Takemoto classification

All patients were given two risk scores, the order of which was randomly determined.

PROCEDURE

EGGIM

All patients were given two risk scores, the order of which was randomly determined.

Sponsors & Collaborators

  • Yanqing Li

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-12
Primary Completion
2024-12-31
Completion
2025-07-04

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05458388 on ClinicalTrials.gov